Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes - Report - MDSpire
Advertisement
Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes
Preet M. Chaudhary, MD, PhD, discusses the repeat ranking of the USC Norris Blood and Marrow Transplant and Cell Therapy Program as one of the nation’s elite allogeneic transplant programs with the highest survival outcomes.
Clinical Report: USC Norris Blood and Marrow Transplant Program Excels in Survival Outcomes
Overview
The USC Norris Blood and Marrow Transplant and Cell Therapy Program has been recognized as one of the top allogeneic transplant programs in the U.S., achieving a +1 performance score from CIBMTR for six consecutive years. With an 86% one-year survival rate, the program demonstrates sustained excellence in managing complex transplant cases.
Background
Allogeneic bone marrow transplantation is a complex procedure primarily used to treat aggressive blood cancers and disorders. Key challenges include managing severely ill patients, selecting appropriate candidates, preventing graft-versus-host disease (GVHD), and controlling infections. Advances such as haploidentical transplants and improved immunosuppressive regimens have expanded donor availability and enhanced outcomes. The USC Norris program integrates multidisciplinary expertise and cutting-edge scientific knowledge to optimize patient care.
Data Highlights
Metric
Value
Context
One-year allogeneic transplant survival rate
86%
Among highest nationally for adult programs
CIBMTR +1 performance score
Achieved
Highest possible score indicating superior survival outcomes
Number of U.S. programs with +1 score (2025)
8
USC Norris is one of these elite programs
Consecutive years with +1 score
6
One of only four programs nationwide
Key Findings
USC Norris program earned the highest +1 CIBMTR score for six consecutive years, reflecting exceptional one-year survival outcomes.
The program’s one-year survival rate after allogeneic transplant is 86%, ranking it among the nation’s best.
Early adoption of haploidentical transplant techniques expanded donor options, especially important in ethnically diverse populations.
Innovative immunosuppressive regimens originally developed for haploidentical transplants were applied broadly, improving outcomes for fully matched transplants.
Multidisciplinary care including specialists across organ systems and psychosocial support contributes to comprehensive patient management.
A cohesive, scientifically driven team approach ensures adherence to best practices and continuous improvement in protocols and workflows.
Clinical Implications
Clinicians should consider early use of haploidentical transplantation and tailored immunosuppressive regimens to improve survival in diverse patient populations. Multidisciplinary collaboration and comprehensive supportive care are critical to managing complex post-transplant complications and optimizing outcomes. Programs aiming for high survival rates must foster integrated teams and apply the latest scientific advances in clinical practice.
Conclusion
The USC Norris Blood and Marrow Transplant and Cell Therapy Program exemplifies sustained excellence in allogeneic transplantation through innovative clinical strategies and multidisciplinary care, achieving survival outcomes that surpass national benchmarks.
References
Preet M. Chaudhary, MD, PhD / Keck Medicine of USC / 2025 -- Bone Marrow Transplant: How Keck Medicine of USC Is Excelling in Survival Outcomes
